SAR 114.0
(-0.18%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | 892.61 Million SAR | 0.54% |
2022 | 887.81 Million SAR | 9.27% |
2021 | 812.52 Million SAR | -4.31% |
2020 | 849.11 Million SAR | 22.7% |
2019 | 692 Million SAR | 13.32% |
2018 | 610.65 Million SAR | -15.33% |
2017 | 721.23 Million SAR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q1 | 232.94 Million SAR | 36.61% |
2024 Q3 | 182.2 Million SAR | -26.46% |
2024 Q2 | 247.73 Million SAR | 6.35% |
2023 Q4 | 170.51 Million SAR | -19.87% |
2023 FY | 892.61 Million SAR | 0.54% |
2023 Q3 | 212.8 Million SAR | -19.68% |
2023 Q2 | 264.95 Million SAR | 8.43% |
2023 Q1 | 244.34 Million SAR | 90.92% |
2022 Q2 | 268.5 Million SAR | 13.05% |
2022 Q1 | 237.5 Million SAR | 65.82% |
2022 Q3 | 253.81 Million SAR | -5.47% |
2022 FY | 887.81 Million SAR | 9.27% |
2022 Q4 | 127.98 Million SAR | -49.57% |
2021 FY | 812.52 Million SAR | -4.31% |
2021 Q4 | 143.23 Million SAR | -42.12% |
2021 Q3 | 247.45 Million SAR | 9.09% |
2021 Q2 | 226.82 Million SAR | 16.31% |
2021 Q1 | 195.01 Million SAR | 16.91% |
2020 Q1 | 294.6 Million SAR | 0.0% |
2020 FY | 849.11 Million SAR | 22.7% |
2020 Q4 | 166.8 Million SAR | 79.18% |
2020 Q3 | 93.09 Million SAR | -65.6% |
2020 Q2 | 270.64 Million SAR | -8.13% |
2019 FY | 692 Million SAR | 13.32% |
2018 FY | 610.65 Million SAR | -15.33% |
2017 FY | 721.23 Million SAR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
Middle East Pharmaceutical Industries Co. | 65.82 Million SAR | -1255.999% |
Al-Dawaa Medical Services Company | 329.22 Million SAR | -171.128% |
Al-Razi Medical Co. | 685.96 Thousand SAR | -130025.332% |
Almujtama Alraida Medical Co. | 11.39 Million SAR | -7734.825% |